# Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

> **NCT06482554** · PHASE3 · RECRUITING · sponsor: **Louisiana State University Health Sciences Center Shreveport** · enrollment: 80 (estimated)

## Conditions studied

- Apathy
- Schizophrenia
- Schizophrenia; Psychosis

## Interventions

- **DRUG:** Lumateperone 42 mg
- **DRUG:** Risperidone 2 mg

## Key facts

- **NCT ID:** NCT06482554
- **Lead sponsor:** Louisiana State University Health Sciences Center Shreveport
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06482554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06482554, "Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06482554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*